Compare Novartis AG (NVS) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Otis Worldwide Corp — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while Otis Worldwide Corp trades at $66.1 (market cap $25.17B). The key difference: Novartis AG is far larger — about 10.7× Otis Worldwide Corp's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Otis Worldwide Corp for 65 Days on average.
| NVS | OTIS | |
|---|---|---|
Market Cap | $268.57B | $25.17B |
Volume | 1,532,573 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $168.62 | $93.62 |
52-Week Low | $121.80 | $64.05 |
Typical Hold Time | 82 Days | 65 Days |
Enterprise Value | $309.89B | $33.20B |
Dividend Yield | 3.31% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Otis Worldwide trades at $65.74, down 1.07% on the day and near its 52-week low, reflecting bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B USD with a net income margin of 10.17%, but faces margin pressure and a high debt-to-asset ratio of 75.54%. Recent news highlights CEO succession plans and mixed sentiment amid weak equipment demand in China.
The outlook is cautious with moderate upside to the $87.00 consensus price target, supported by a dominant service segment and institutional accumulation. Key risks include persistent margin compression, China exposure, and elevated leverage, requiring monitoring of service margin recovery for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
